S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
Log in

NASDAQ:BPMC - Blueprint Medicines Stock Price, Forecast & News

$70.37
-8.11 (-10.33 %)
(As of 12/9/2019 04:00 PM ET)
Today's Range
$69.77
Now: $70.37
$77.00
50-Day Range
$67.55
MA: $74.86
$82.16
52-Week Range
$44.58
Now: $70.37
$102.98
Volume1.08 million shs
Average Volume463,917 shs
Market Capitalization$3.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.65
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BPMC
CUSIPN/A
Phone617-374-7580

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$44.52 million
Book Value$9.55 per share

Profitability

Net Income$-236,640,000.00
Net Margins-2,258.84%

Miscellaneous

Employees217
Market Cap$3.46 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive BPMC News and Ratings via Email

Sign-up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.


Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Corp (NASDAQ:BPMC) issued its earnings results on Tuesday, November, 5th. The biotechnology company reported ($1.93) EPS for the quarter, topping the consensus estimate of ($2.19) by $0.26. The biotechnology company earned $9.14 million during the quarter, compared to analysts' expectations of $2.85 million. Blueprint Medicines had a negative return on equity of 77.27% and a negative net margin of 2,258.84%. Blueprint Medicines's quarterly revenue was up 734.6% compared to the same quarter last year. During the same period last year, the business earned ($1.66) earnings per share. View Blueprint Medicines' Earnings History.

When is Blueprint Medicines' next earnings date?

Blueprint Medicines is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Blueprint Medicines.

What price target have analysts set for BPMC?

11 analysts have issued 12-month target prices for Blueprint Medicines' shares. Their forecasts range from $75.00 to $125.00. On average, they expect Blueprint Medicines' stock price to reach $105.50 in the next twelve months. This suggests a possible upside of 49.9% from the stock's current price. View Analyst Price Targets for Blueprint Medicines.

What is the consensus analysts' recommendation for Blueprint Medicines?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 1 sell rating, 1 hold rating, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Blueprint Medicines.

Has Blueprint Medicines been receiving favorable news coverage?

News articles about BPMC stock have been trending extremely negative on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Blueprint Medicines earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Blueprint Medicines.

Are investors shorting Blueprint Medicines?

Blueprint Medicines saw a drop in short interest in November. As of November 15th, there was short interest totalling 3,370,000 shares, a drop of 6.1% from the October 31st total of 3,590,000 shares. Based on an average trading volume of 468,100 shares, the short-interest ratio is currently 7.2 days. Approximately 7.0% of the shares of the stock are sold short. View Blueprint Medicines' Current Options Chain.

Who are some of Blueprint Medicines' key competitors?

What other stocks do shareholders of Blueprint Medicines own?

Who are Blueprint Medicines' key executives?

Blueprint Medicines' management team includes the folowing people:
  • Mr. Jeffrey W. Albers, CEO, Pres & Director (Age 48)
  • Mr. Alexis A. Borisy, Co-Founder & Director (Age 47)
  • Mr. Michael Landsittel, Chief Financial Officer (Age 47)
  • Ms. Kathryn Haviland, Chief Operating Officer (Age 43)
  • Dr. Christopher K. Murray, Sr. VP of Technical Operations (Age 56)

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (3.72%), TimesSquare Capital Management LLC (1.73%), Eagle Asset Management Inc. (1.56%), Pictet Asset Management Ltd. (1.07%), Voya Investment Management LLC (0.71%) and California Public Employees Retirement System (0.19%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Daniel Lynch, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View Institutional Ownership Trends for Blueprint Medicines.

Which major investors are selling Blueprint Medicines stock?

BPMC stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Man Group plc, Great West Life Assurance Co. Can, NBW Capital LLC and Rhumbline Advisers. Company insiders that have sold Blueprint Medicines company stock in the last year include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View Insider Buying and Selling for Blueprint Medicines.

Which major investors are buying Blueprint Medicines stock?

BPMC stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Voya Investment Management LLC, Pictet Asset Management Ltd., TimesSquare Capital Management LLC, California Public Employees Retirement System, State of New Jersey Common Pension Fund D, First Trust Advisors LP and Russell Investments Group Ltd.. View Insider Buying and Selling for Blueprint Medicines.

How do I buy shares of Blueprint Medicines?

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $70.37.

How big of a company is Blueprint Medicines?

Blueprint Medicines has a market capitalization of $3.46 billion and generates $44.52 million in revenue each year. The biotechnology company earns $-236,640,000.00 in net income (profit) each year or ($5.39) on an earnings per share basis. Blueprint Medicines employs 217 workers across the globe.View Additional Information About Blueprint Medicines.

What is Blueprint Medicines' official website?

The official website for Blueprint Medicines is http://www.blueprintmedicines.com/.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]


MarketBeat Community Rating for Blueprint Medicines (NASDAQ BPMC)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  398 (Vote Outperform)
Underperform Votes:  272 (Vote Underperform)
Total Votes:  670
MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines and other stocks. Vote "Outperform" if you believe BPMC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel